LAS VEGAS, Nov. 30 /PRNewswire-FirstCall/ -- VMT Scientific Inc. (OTC:VMTF.PK) After extensive meetings and discussions with the board of directors, it was adopted on November 29, 2005 that VMT Scientific, Inc., will form a fully funded official Medical Advisory Board made up of some of the nation's top medical doctors and researchers in their applied fields. VMT Scientific will seek out these professionals to oversee the planned FDA approved clinical trials and to advise on its new model testing and development. Bowing to public and professional pressure to accelerate the medical testing phase of this technology, VMT Scientific feels it prudent to move ahead with this step at this time. This Press Release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on these forward-looking statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those suggested in the forward- looking statements, particularly those risks and uncertainties inherent in the process of developing, medical products and Clinical trials. Factors that may cause such a difference include risks related to VMT Scientific Inc.'s limited operating history, risks associated with completing development and obtaining FDA medical approvals, successful patent protection and prosecution, successful sale of licensed technology nationally or internationally. VMT Scientific technology will not meet with market acceptance, the risk of future warranty and product liability claims, the uncertainty of VMT Scientifics' future access to capital to sustain operations, achieve profitability or continue as a going concern, the failure by VMT Scientific to secure and maintain relationships with suppliers, manufacturers and other third parties, reliance on key employees, and dependence on intellectual property. These forward-looking statements are based on information and management's expectations as of the date hereof. Future results may differ materially from our current expectations. DATASOURCE: VMT Scientific, Inc. CONTACT: Catherine S. Ratelle, Director of Operations, VMT Scientific, Inc., +1-702-990-3477 Web site: http://www.vmtf.org/

Copyright